Canine
Update (June 10, 2026): 2026 Review Maps the Modern Canine Atopic Dermatitis Treatment Toolkit
TL;DR
An April 2026 review of the newest therapeutic methods for canine atopic dermatitis maps the current toolkit - glucocorticoids, cyclosporine, JAK inhibitors, lokivetmab and immunotherapy - and reinforces the consensus that effective management is multimodal and individualised.
What just dropped
Mazilu, Strichea and Solcan published "Some of the Newest Therapeutic Methods in Canine Atopic Dermatitis" in Veterinary Sciences (April 2026; PMID 42076775; DOI 10.3390/vetsci13040403), from the Faculty of Veterinary Medicine, Iasi University of Life Sciences, Romania.
- The review summarises the principal treatment modalities currently available for canine atopic dermatitis (AD): glucocorticoids, cyclosporine A, mycophenolate, Janus kinase inhibitors, lokivetmab, and allergen-specific immunotherapy, plus complementary strategies aimed at restoring skin-barrier integrity.
- It characterises AD as a hereditary, chronic, inflammatory and pruritic skin disease that is T-cell mediated and requires long-term, individualised management.
- It groups interventions into fast-acting symptomatic treatments, long-term immune-modulating interventions, and strategies to support skin-barrier function and microbial balance.
- It emphasises a multimodal and personalised approach to optimise long-term disease control and quality of life in affected dogs.
Context
This 2026 review arrives a decade after the International Committee on Allergic Diseases of Animals (ICADA) 2015 consensus guidelines (Olivry et al.; PMID 26276051), which remain a touchstone for evidence-based canine AD management. The ICADA guidelines identified the medications then most effective for reducing chronic pruritus and skin lesions as topical and oral glucocorticoids, oral ciclosporin and oral oclacitinib, and stressed that AD management is multifaceted, with interventions combined for optimal benefit. The newer review extends that landscape to explicitly include the anti-IL-31 biologic lokivetmab and other agents, while echoing the same core principle: no single drug is sufficient, and plans must be tailored to the patient and disease stage.
For clinicians, the value is in seeing how the established agents (cyclosporine, oclacitinib) and newer biologics (lokivetmab) fit together within one framework rather than competing as isolated options.
What this changes across the canine atopic dermatitis evergreens
This review touches three Voyage for Vets evergreens - cyclosporine (https://www.thevoyage.ai/forvets/knowledge/cyclosporine-canine-atopic-dermatitis), oclacitinib (https://www.thevoyage.ai/forvets/knowledge/oclacitinib-canine-atopic-dermatitis), and lokivetmab (https://www.thevoyage.ai/forvets/knowledge/lokivetmab-cytopoint-canine-atopic-dermatitis) - by placing each within a single, current treatment map. It confirms that cyclosporine A remains a recognised long-term immune-modulating option, that JAK inhibition (oclacitinib) is part of the standard armamentarium, and that lokivetmab is now an established biologic choice. The unifying message, consistent with ICADA 2015, is that these agents are most effective when selected and combined as part of a multimodal, individualised plan rather than ranked as a single best drug. As a narrative review, it summarises rather than generates new trial data.
References
- Mazilu CC, Strichea AH, Solcan G. Some of the Newest Therapeutic Methods in Canine Atopic Dermatitis. Vet Sci. 2026;13(4):403. https://pubmed.ncbi.nlm.nih.gov/42076775/
- Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210. https://pubmed.ncbi.nlm.nih.gov/26276051/
Voyage Clinical Desk
From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.
Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-10-canine-ad-therapeutics-review
Changelog
- 2026-06-10: First published.
Related reads
References
More clinical updates
Update (June 10, 2026): Bedinvetmab Non-Inferior to Grapiprant for Canine OA Pain on Force-Plate Gait Analysis
A February 2026 randomized non-inferiority trial using force-plate gait analysis found bedinvetmab non-inferior to grapiprant for canine osteoarthritis pain, supporting both as first-line options.
Read →Update (June 10, 2026): No Evidence of Circulating RAAS Activation in Cats with Non-Hypertensive CKD or Untreated Hypertension
A May 2026 JVIM study measuring circulating RAAS peptides in cats found no evidence of classical RAAS activation in non-hypertensive CKD or untreated hypertension, refining the rationale for RAAS-targeted therapy.
Read →Update (June 10, 2026): Oclacitinib Resolves Canine Reactive Histiocytosis in a 10-Dog Case Series
A 2026 Vet Dermatol case series of 10 dogs found oclacitinib monotherapy rapidly resolved reactive histiocytosis, including cases refractory to other immunomodulators - an emerging off-label use.
Read →Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence
Lokivetmab (Cytopoint) neutralizes IL-31 to control pruritus in canine atopic dermatitis. Evidence from pivotal RCTs, a 12-month cohort, and combination therapy data reviewed.
Read →